CLDX vs PHVS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CLDX · Celldex Therapeutics$29.87 ▲ 5.66%
PHVS · Pharvaris$34.39 ▲ 5.72%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CLDX +31.8%
- PHVS +52.0%
Head to head
| Metric | CLDX | PHVS |
|---|---|---|
| Price | $29.87 | $34.39 |
| Change today | ▲ 5.66% | ▲ 5.72% |
| Market cap | $2.35B | $2.41B |
| Return, 3 months | -30.5% | -1.3% |
| Return, year to date | +10.0% | +23.9% |
| Return, 1 year | +30.4% | +59.3% |
| P/E (TTM) | -7.0 | -11.8 |
| P/B | 3.6 | 7.2 |
| P/E percentile vs own 5y | 97th | 8th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -97.0% | – |
| Net profit growth (YoY) | -29.9% | -5.2% |
| Gross margin | – | – |
| Operating margin | -206,220.3% | – |
| Net margin | -190,220.9% | – |
| Return on equity | -43.9% | -70.5% |
| Analyst target vs. price | +133.7% | +78.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 59 |
| 30-day volatility | 50.1% | 45.0% |
| Max drawdown, 1 year | -38.6% | -28.6% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PHVS is the largest of the group by market value.
- PHVS has returned the most over the past year.
- PHVS carries the lowest trailing P/E.
- PHVS has been the calmest stock over the last 30 days.